Pancreatic Cancer Research

ResearcherThe Royal Free HospitalActive in the last 2 years

Brian Ritchie Davidson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9152-5907; OpenAlex author ID A5045604232. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 5 papers · 2024: 1 paper · 2025: 3 papers

Papers 18

  1. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  2. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  3. Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma-A Multicentre Propensity Score Matching Analysis of the Recurrence After Whi… Co-author DOI 10.3390/cancers17071223↗
  4. Five-year recurrence/survival after pancreatoduodenectomy for pancreatic adenocarcinoma: does pre-existing diabetes matter? Results from the Recurrence After W… Co-author DOI 10.1016/j.hpb.2024.04.010↗
  5. Role of circulating exosomal biomarkers and their diagnostic accuracy in pancreatic cancer. Co-author DOI 10.1002/jgh3.12848↗
  6. Nanotechnology-augmented sonodynamic therapy and associated immune-mediated effects for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-022-04418-y↗
  7. Correction to: Nanotechnology-augmented sonodynamic therapy and associated immune-mediated effects for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-023-04648-8↗
  8. Does an extensive diagnostic workup for upfront resectable pancreatic cancer result in a delay which affects survival? Results from an international multicentr… Co-author DOI 10.14701/ahbps.23-042↗
  9. Management of Pain and Cachexia in Pancreatic Cancer: Protocol for Two Systematic Reviews, Network Meta-Analysis, Surveys, and Focus Groups. Co-author DOI 10.2196/46335↗
  10. Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-… Last author DOI 10.1136/bmjopen-2021-050166↗
  11. 5-Aminolevulinic acid for fluorescence-guided surgery in pancreatic cancer: Cellular transport and fluorescence quantification studies. Co-author DOI 10.1016/j.tranon.2020.100886↗
  12. Irreversible Electroporation (IRE) in Locally Advanced Pancreatic Cancer: A Review of Current Clinical Outcomes, Mechanism of Action and Opportunities for Syne… Last author DOI 10.3390/jcm10081609↗
  13. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-gluco… Co-author DOI 10.3310/hta22070↗
  14. Cost-effectiveness of laparoscopic versus open distal pancreatectomy for pancreatic cancer. Co-author DOI 10.1371/journal.pone.0189631↗
  15. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/14651858.cd011391.pub2↗
  16. Pancreatic cancer tissue banks: where are we heading? Co-author DOI 10.2217/fon-2016-0243↗
  17. Resection versus other treatments for locally advanced pancreatic cancer. Co-author DOI 10.1002/14651858.cd010244.pub2↗
  18. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated wit… Co-author DOI 10.1111/hpb.12019↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kurinchi Selvan Gurusamy · 5 shared papers, 2014–2023 · strength 0.51
  2. Peter Lawrence Zaki Labib · 3 shared papers, 2021–2025 · strength 0.45
  3. Andrew Malvern Smith · 3 shared papers, 2018–2025 · strength 0.33
  4. Giuseppe Fusai · 3 shared papers, 2013–2023 · strength 0.32
  5. Marym Mohammad-Hadi · 2 shared papers, 2023 · strength 0.31
  6. John F. Callan · 2 shared papers, 2023 · strength 0.31
  7. Nikolitsa Nomikou · 2 shared papers, 2023 · strength 0.31
  8. A. P. McHale · 2 shared papers, 2023 · strength 0.31
  9. Heather Nesbitt · 2 shared papers, 2023 · strength 0.31
  10. Zainab L. Rai · 2 shared papers, 2021–2022 · strength 0.31
  11. Derek Manas · 2 shared papers, 2021–2022 · strength 0.31
  12. Duncan R.C. Spalding · 2 shared papers, 2023–2025 · strength 0.28
  13. Alberto Porcu · 2 shared papers, 2023–2025 · strength 0.28
  14. Thomas Brendon Russell · 2 shared papers, 2023–2025 · strength 0.28
  15. Fabio Ausania · 2 shared papers, 2023–2025 · strength 0.28
  16. Ricky Harminder Bhogal · 2 shared papers, 2023–2025 · strength 0.28
  17. Somaiah Aroori · 2 shared papers, 2023–2025 · strength 0.28
  18. Ismael Domínguez-Rosado · 2 shared papers, 2023–2025 · strength 0.28
  19. Dhanny Gomez · 2 shared papers, 2023–2025 · strength 0.28
  20. Manuel Maglione · 2 shared papers, 2023–2025 · strength 0.28
  21. Keith John Roberts · 2 shared papers, 2023–2025 · strength 0.28
  22. Zaed Z. R. Hamady · 2 shared papers, 2023–2025 · strength 0.28
  23. Daniel Gerald Croagh · 2 shared papers, 2023–2025 · strength 0.28
  24. Elizabeth Pando · 2 shared papers, 2023–2025 · strength 0.28
  25. Adam Enver Frampton · 2 shared papers, 2023–2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.